Serum markers to predict the clinical response to anti -TNFα antibodies in patients with ankylosing spondylitis

摘要

Prior to initiation of therapy with anti -TNFα agent, the present invention provides a tool for managing patients with a diagnosis of ankylosing spondylitis. Tool, an algorithm and a particular marker on the basis of the secondary endpoints and primary clinical standard using a serum marker concentrations, predicting the response to therapy. In one embodiment, using the baseline levels of osteocalcin or leptin, and predicting the response in the first 14 weeks after initiation of therapy. In another embodiment, I use the change in serum protein biomarkers of complement component 3 of the first 4 weeks after treatment.